Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 5/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258082 | 1.00 | ADRA2A (0.50) | ADRA2AMCHR1EPHX2NPY5RKDM1A | |
| SCHEMBL15359447 | 0.88 | EPHX2 (0.55) | ADRA2AMCHR1EPHX2NPY5RMEN1 | |
| SCHEMBL30400350 | 0.85 | AAK1 (0.44) | KDM1AMAOBAAK1DRD2KMT2A | |
| SCHEMBL23124560 | 0.84 | MCHR1 (0.59) | ADRA2AMCHR1EPHX2NPY5RHTT | |
| SCHEMBL14606862 | 0.81 | MCHR1 (0.57) | ADRA2AMCHR1EPHX2NPY5RHTT | |
| SCHEMBL3710703 | 0.81 | EPHX2 (0.51) | ADRA2AMCHR1EPHX2NPY5RAAK1 | |
| SCHEMBL3947055 | 0.80 | MCHR1 (0.54) | ADRA2AMCHR1NPY5RKDM1AMAOB | |
| SCHEMBL3947061 | 0.80 | MCHR1 (0.54) | ADRA2AMCHR1NPY5RKDM1AMAOB | |
| SCHEMBL4262295 | 0.79 | MCHR1 (0.55) | ADRA2AMCHR1EPHX2NPY5RKDM1A | |
| SCHEMBL4262293 | 0.79 | MCHR1 (0.55) | ADRA2AMCHR1EPHX2NPY5RKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| EP-1464335-A2 | Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | ADRA2A 117/4885MCHR1 2/4885EPHX2 1053/4885 |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | ADRA2A 178/4885MCHR1 3/4885EPHX2 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.